top of page
  • Writer's pictureLaurent DECORY

UCB’s Bimekizumab to reshape psoriasis market

The $ 20+ billion Psoriasis treatment market has been dominated by AbbVie's Humira.

But things might change soon.

After beating J&J’s Stelara and AbbVie’s Humira, UCB’s Bimekizumab now wins over Novartis’s Cosentyx, with potential to reshape busy psoriasis market.

5 views0 comments


bottom of page